Geneo x L.E.K. Consulting x BCS Singapore Life Science Case Competition 2025

Wonder Wang, Engagement Manager, Asia Healthcare, L.E.K. Consulting Singapore

Wonder Wang is a Manager in L.E.K.’s Singapore office, specializing in the Healthcare and Life Sciences Practice. He has over 8 years of experience across pharma and medtech sectors. He has worked with clients across Southeast Asia and Asia-Pacific on go-to-market strategy, market access strategy and M&A. He obtained his Beng and MSc in Biomaterial science from HKUST. Wonder also has 2 years working experience in private equity firm focusing on medtech industry in Asia, he has first-hand experience from product R&D to commercialization in APAC market.

Alex Soh, Senior Consultant, Asia Healthcare, L.E.K. Consulting Singapore

Alex Soh is a Senior Consultant in L.E.K. Singapore office, specializing in the Healthcare and Life Sciences Practice. He has extensive experience leading teams in delivering due diligence, market entry, and growth strategy projects for leading healthcare clients. Prior to joining L.E.K., Alex spent over seven years in Singapore’s public healthcare sector as a registered pharmacist and Strategy Manager at the National University Health System (NUHS). In this role, he spearheaded clinical service integration and care transformation initiatives. Alex holds an MBA from INSEAD and a Master of Pharmacy (MPharm) from University College London (UCL).

Shri Sarkar, Partner, Asia Healthcare, L.E.K. Consulting Singapore

Shri Sarkar is a Partner in L.E.K. Consulting’s Healthcare practice, based in Singapore. He has over 15 years of experience in the life sciences and healthcare sectors across Southeast Asia, India, and the broader Asia-Pacific region.

Prior to joining L.E.K., Shri was a Managing Director at an Asia-focused private equity firm, where he led value creation and transformation initiatives for healthcare investments across the portfolio. Before that, he headed the Southeast Asia and Asia-Pacific Regional HQs life sciences consulting practice at IQVIA, advising leading biopharmaceutical and healthcare private equity clients on growth strategy, market entry, product launch, pricing and market access, commercial excellence, and due diligence.

Navjeewan Khosla, Partner, Novo Holdings Asia

Nav joined Novo Holdings Asia in August 2021. He focusses on deal sourcing and execution as well as in managing and developing the growing portfolio of investments, focusing primarily on the markets in China, India, and Southeast Asia.

Prior to joining Novo Holdings Asia, Nav was a Director in Quadria Capital, a mid-market private equity firm focusing on healthcare investments in India and South East Asia. Before joining Quadria Capital, Nav was the Managing Director at Fosun, where he worked on both private and public healthcare investment opportunities across the Asia-Pacific region. Nav started his investment career with Merrill Lynch in Hong Kong and moved to UBS Global Asset Management in Singapore before joining Fosun.

Nav holds an MBA from Indian Institute of Management (IIM), Ahmedabad, in India and Bachelor of Technology from Indian institute of Technology (IIT), Kharagpur in India.

Ronne Yeo, Head of Venture Relations, JLABS Singapore

JLABS is a global life sciences incubator network and a part of Johnson & Johnson’s external scientific innovation unit. As Head of Venture Relations, Ronne works with venture capital firms to identify high potential companies from their portfolio.

Ronne has accumulated more than 10 years of experience in life sciences innovation, in areas including venture investment, company creation, R&D, IP strategy and business development. He was formerly Managing Director at EVX Ventures where he managed its deal sourcing, due diligence, portfolio management and talent development. EVX Ventures built and managed a biotech portfolio comprising notable companies such as AltruBio and Hummingbird Biosciences. He was Founding VP of Discovery of Carmine Therapeutics, a non-viral gene therapy company that successfully secured a USD 900M research collaboration with Takeda. He was also Cofounder, CSO and Head of BD for Carcell Biopharma, a company developing cell therapy for autoimmune diseases and lipid nanoparticles for nucleic acid deliveries. Both companies collectively raised over USD 40M.

Ronne holds a PhD in Biological Sciences from National University of Singapore and is an inventor on 6 patent families and author of several peer-reviewed publications.

Gregory Lee, Vice President, Head of Global Commercial Strategy, Santen Pharmaceutical

Gregory Lee is a seasoned pharmaceutical executive and physician with 18 years of experience in the healthcare and biopharmaceutical industry. He currently serves as Vice President, Head of Global Commercial Strategy at Santen Pharmaceutical, based in Singapore. In this global role, Gregory leads the development and execution of commercial strategies across Santen’s ophthalmology portfolio—spanning early-stage pipeline assets to new product launches.

In addition to Santen’s core therapeutic areas of glaucoma, dry eye, and ocular infection, he also oversees the commercial strategy and global marketing for new brands in myopia and ptosis, playing a key role in driving Santen’s expansion into emerging ophthalmic segments.

Since joining Santen, Gregory has been instrumental in transforming the company’s strategic capabilities. As Head of Medical Affairs for Asia, he built the regional function from the ground up—supporting multiple product launches and shaping lifecycle strategies across diverse Asian markets. Transitioning into commercial leadership, he led high-impact strategic initiatives, including the design of a cross-functional strategy framework to maximize asset value. He also played a critical role in evaluating and shaping global portfolio opportunities, directly influencing Santen’s long-term therapeutic focus.

Prior to joining Santen, Gregory held global leadership roles at Sirtex Medical, where he directed medical affairs for the company’s interventional oncology portfolio. He led efforts in clinical evidence generation, market expansion planning, and stakeholder engagement across international regions.